Browse All

Current Filters

CLEAR FILTER x

TITLE

Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Hauser, Stephen   Bar-Or, Amit   Gold, Ralf   Montalban, Xavier   Cohen, Jeffrey   Robertson, Derrick   Hersh, Carrie   Naismith, Robert   Deiva, Kumaran   Bhatt, Alit   Fu, Haoyi   Boer, Ibolya   Meuth, Sven   Cross, Anne   Gärtner, Jutta   Kappos, Ludwig   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.003  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma, USA, Oklahoma City, OK  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA, San Francisco, CA  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Department of Neurology, Katholisches Klinikum Bochum, Ruhr-Universität Bochum, Bochum, Germany, Bochum, Germany  Department of Neurology Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, Florida, USA, Tampa, FL  Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States, Las Vegas, NV  Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA, Saint Louis, MO  Department of Pediatric Neurology, University Hospitals Paris Saclay, Hôpital Bicêtre, National Reference Center for Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology, Section of Neuroimmunology, Washington University School of Medicine, Saint Louis, Missouri, USA, Clayton, MO  Department of Paediatrics and Adolescent Medicine, Division of Paediatric Neurology, University Medical Centre Göttingen, Georg August University Göttingen, Göttingen, Germany, Göttingen, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Organs, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial

Author:Steinman, Lawrence   Selmaj, Krzysztof   Comi, Giancarlo   Bar-Or, Amit   Arnold, Douglas   Hartung, Hans-Peter   Montalban, Xavier   Havrdova, Eva   Sheffield, James   Cheng, Chun-Yen   Reardon, Jennifer   Riolo, Jon   Deboer, Erik   Kappos, Ludwig   Cohen, Jeffrey   Cree, Bruce   

Session Name:P2: Multiple Sclerosis: Clinical Practice and Decision Making 2  

Topic:Multiple Sclerosis  

Program Number:P2.007  

Author Institution:Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Center for Neurology, Lódz, Poland, and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Lodz, Poland  Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montreal, QC, Canada  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic, Prague, Czech Republic  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  

Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials

Author:Filippi, Massimo   Riolo, Jon   Cohen, Jeffrey   Hartung, Hans-Peter   Montalban, Xavier   Meuth, Sven   Freeman, Leorah   Chitnis, Tanuja   Granziera, Cristina   Deboer, Erik   Cheng, Chun-Yen   Reardon, Jennifer   Pachai, Chahin   Sheffield, James   Cree, Bruce   Kappos, Ludwig   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.014  

Author Institution:Neuroimaging Research Unit, Division of Neuroscience, Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy, Milan, Italy  Bristol Myers Squibb, Princeton, New Jersey, USA, Princeton, NJ  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, Duesseldorf, Germany  Dell Medical School, The University of Texas at Austin, Austin, Texas, USA, Austin, TX  Brigham and Women’s Hospital, and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, Boston, MA  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland  Department of Neurology, University Hospital Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Bristol Myers Squibb, Princeton, New Jersey, USA, New York, NY  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA , San Francisco, CA  

Eight-point Reliable Change on Symbol Digit Modalities Test with Ozanimod: Findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials

Author:DeLuca, John   Cohen, Jeffrey   Cree, Bruce   Comi, Giancarlo   Kappos, Ludwig   Cheng, Chun-Yen   Sheffield, James   Riolo, Jon   Thorpe, Andrew   Benedict, Ralph   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.015  

Author Institution:Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, San Francisco, CA  Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy, Milan, Italy  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Jacobs MS Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, Buffalo, NY  

Assessing the Impact of Immune Checkpoint Inhibitor Therapy on Clinical and MRI Activity in Patients with Multiple Sclerosis

Author:Afzal, Saira   Li, Yadi   Lapin, Brittany   Boyce Kennedy, Lucy   Cohen, Jeffrey   McGinley, Marisa   Kunchok, Amy   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.003  

Author Institution:Cleveland Clinic , Weston, FL  Cleveland Clinic , Cleveland, OH  Cleveland Clinic, Cleveland, OH  Cleveland Clinic - Mellen Center, Cleveland, OH